	US 11,938,174 B2
	Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
Colin Broom, Devon, PA (US); and Jeffrey Dayno, Maple Glen, PA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Sep. 11, 2020, as Appl. No. 17/018,954.
Application 17/018,954 is a continuation of application No. 16/293,134, filed on Mar. 5, 2019, granted, now 10,786,557.
Application 16/293,134 is a continuation of application No. 14/539,405, filed on Nov. 12, 2014, granted, now 10,272,142, issued on Apr. 30, 2019.
Claims priority of provisional application 61/903,643, filed on Nov. 13, 2013.
Prior Publication US 2021/0236607 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/55 (2006.01); A61K 35/16 (2015.01); A61K 38/57 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01)

CPC A61K 38/57 (2013.01) [A61K 35/16 (2013.01); A61K 38/55 (2013.01); A61K 45/06 (2013.01); A61K 39/3955 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01)]

9 Claims

1. A method of treating or delaying the progression of a central nervous system (CNS) disorder alleviated by inhibiting complement immune system activation in a patient in need of such treatment, the method comprising administering to said patient at the onset of an active CNS attack one or more doses of at least 2000 U of C1-esterase inhibitor (C1-INH) per dose, wherein said disorder is neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD).